UY27735A1 - Hidrato de un antagonista de receptores muscarínicos. - Google Patents

Hidrato de un antagonista de receptores muscarínicos.

Info

Publication number
UY27735A1
UY27735A1 UY27735A UY27735A UY27735A1 UY 27735 A1 UY27735 A1 UY 27735A1 UY 27735 A UY27735 A UY 27735A UY 27735 A UY27735 A UY 27735A UY 27735 A1 UY27735 A1 UY 27735A1
Authority
UY
Uruguay
Prior art keywords
bladder
antagonist
treatment
hydrate
syndrome
Prior art date
Application number
UY27735A
Other languages
English (en)
Inventor
Peter J Dunn
John G Matthews
Trevor J Newbury
Garry O Connor
Original Assignee
Novartis Int Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9933731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY27735(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Int Pharm Ltd filed Critical Novartis Int Pharm Ltd
Publication of UY27735A1 publication Critical patent/UY27735A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un hidrato sólido establece de un antagonista de receptores muscarínicos es útil en el tratamiento de síndrome de intestino irritable, enfermedades diverticular, acalasia esofágica, enfermedad obstructiva crónica de las vías respiratorias, vejiga hiperactiva que incluye los síntomas de incontinencia, urgencia y tratamiento del trastorno funcional de la vejiga, pérdida de orina, dolor o dificultad de la micción causada por la vejiga neurogénica, vejiga espástica o hipertónica, síndrome de vejiga disfuncional, trastornos gastrointestinal que incluyen hiperactividad gastrointestinal, y efecto relajante en las células del músculo liso intestinal.
UY27735A 2002-03-26 2003-03-25 Hidrato de un antagonista de receptores muscarínicos. UY27735A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0207104.1A GB0207104D0 (en) 2002-03-26 2002-03-26 Stable hydrate of a muscarinic receptor antagonist

Publications (1)

Publication Number Publication Date
UY27735A1 true UY27735A1 (es) 2003-10-31

Family

ID=9933731

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27735A UY27735A1 (es) 2002-03-26 2003-03-25 Hidrato de un antagonista de receptores muscarínicos.

Country Status (23)

Country Link
US (3) US6930188B2 (es)
EP (2) EP1490357B1 (es)
JP (2) JP2005524678A (es)
KR (4) KR20120098888A (es)
CN (1) CN100345840C (es)
AR (1) AR042608A1 (es)
AT (1) ATE495169T1 (es)
AU (1) AU2003209921A1 (es)
BR (2) BRPI0308706B8 (es)
CA (1) CA2480287C (es)
CY (2) CY1111200T1 (es)
DE (1) DE60335711D1 (es)
DK (2) DK2336124T3 (es)
ES (2) ES2358644T3 (es)
GB (1) GB0207104D0 (es)
HK (2) HK1080847A1 (es)
PA (1) PA8569701A1 (es)
PT (2) PT1490357E (es)
SI (2) SI2336124T1 (es)
SV (1) SV2003001515A (es)
TW (1) TW200306816A (es)
UY (1) UY27735A1 (es)
WO (1) WO2003080599A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
AU2006239941A1 (en) * 2005-04-24 2006-11-02 Wyeth Methods for modulating bladder function
US20070197630A1 (en) * 2005-12-27 2007-08-23 Valeriano Merli Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
EP2109601A2 (en) * 2007-01-05 2009-10-21 Dr. Reddy's Laboratories Ltd. Preparation of darifenacin and its salts
RU2452728C2 (ru) * 2007-02-23 2012-06-10 Тереванс, Инк. Четвертичные аммониевые дифенилметилсоединения, применимые в качестве антагонистов мускариновых рецепторов
WO2008144602A1 (en) * 2007-05-18 2008-11-27 Auspex Pharmaceuticals, Inc. Deuterated zamifenacin derivatives
WO2009007853A2 (en) * 2007-06-08 2009-01-15 Actavis Group Ptc Ehf Novel polymorphs of darifenacin free base and its hydrobromide salt
US20090005431A1 (en) * 2007-06-30 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
AR068322A1 (es) * 2007-07-13 2009-11-11 Medichem Sa Forma amorfa de hidrobromuro de darifenacina y procedimientos para su preparacion
CZ200845A3 (cs) 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009125426A2 (en) * 2008-02-08 2009-10-15 Neuland Laboratories Ltd NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE
EP2261205A4 (en) 2008-04-02 2012-06-06 Kaneka Corp PROCESS FOR PRODUCING (S) -3- (1-CYANO-1,1-DIPHENYLMETHYL) -PYRROLIDINE
WO2010032225A2 (en) * 2008-09-22 2010-03-25 Watson Pharma Private Limited Process for preparation of darifenacin and intermediates used in the process
EP2236509A1 (en) 2009-04-01 2010-10-06 Ragactives, S.L. Method for obtaining 1,3-difunctionalized pyrrolidine derivatives
WO2011070419A1 (en) 2009-12-10 2011-06-16 Aurobindo Pharma Limited An improved process for the preparation of darifenacin hydrobromide
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
AU2016371762A1 (en) * 2015-12-14 2018-06-21 Cyclerion Therapeutics, Inc. Use of sGC stimulators for the treatment of gastrointestinal sphincter dysfunction
DK3497075T3 (da) * 2016-08-12 2020-08-31 Bayer Cropscience Ag Fremgangsmåde til fremstilling af substituerede styren-derivater

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB8906166D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
AU4421697A (en) * 1996-09-19 1998-04-14 American Home Products Corporation Method of treating urinary incontinence
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist

Also Published As

Publication number Publication date
US7696357B2 (en) 2010-04-13
US20050245597A1 (en) 2005-11-03
CY1113433T1 (el) 2016-06-22
BR0308706A (pt) 2005-01-04
CN1642945A (zh) 2005-07-20
HK1080847A1 (en) 2006-05-04
ES2394067T3 (es) 2013-01-16
CY1111200T1 (el) 2015-06-11
ES2358644T3 (es) 2011-05-12
SV2003001515A (es) 2003-12-15
ATE495169T1 (de) 2011-01-15
AU2003209921A1 (en) 2003-10-08
TW200306816A (en) 2003-12-01
CA2480287A1 (en) 2003-10-02
HK1156626A1 (en) 2012-06-15
KR20100101182A (ko) 2010-09-16
EP1490357A1 (en) 2004-12-29
US20030191176A1 (en) 2003-10-09
DE60335711D1 (de) 2011-02-24
AR042608A1 (es) 2005-06-29
KR101212908B1 (ko) 2012-12-14
SI2336124T1 (sl) 2012-12-31
JP2005524678A (ja) 2005-08-18
SI1490357T1 (sl) 2011-05-31
BRPI0308706B8 (pt) 2021-05-25
PA8569701A1 (es) 2003-12-10
DK2336124T3 (da) 2012-12-17
BR122018000397B8 (pt) 2021-07-27
JP2010195828A (ja) 2010-09-09
KR20040093477A (ko) 2004-11-05
KR101026283B1 (ko) 2011-03-31
US20080167367A1 (en) 2008-07-10
EP2336124B1 (en) 2012-08-29
EP2336124A1 (en) 2011-06-22
KR20110130539A (ko) 2011-12-05
CN100345840C (zh) 2007-10-31
WO2003080599A1 (en) 2003-10-02
US6930188B2 (en) 2005-08-16
GB0207104D0 (en) 2002-05-08
BRPI0308706B1 (pt) 2018-07-10
PT2336124E (pt) 2012-12-12
KR20120098888A (ko) 2012-09-05
CA2480287C (en) 2011-05-31
PT1490357E (pt) 2011-03-01
DK1490357T3 (da) 2011-04-04
EP1490357B1 (en) 2011-01-12
BR122018000397B1 (pt) 2019-07-02

Similar Documents

Publication Publication Date Title
UY27735A1 (es) Hidrato de un antagonista de receptores muscarínicos.
Scivoletto et al. Clinical factors that affect walking level and performance in chronic spinal cord lesion patients
Gagnon et al. Melatonin and comorbidities in children with autism spectrum disorder
NO20054959D0 (no) Fremgangsmater for behandling av interleukin-6 relaterte sykdommer
Pandi-Perumal et al. Could agomelatine be the ideal antidepressant?
US20060173052A1 (en) Use of the non-opiate analgesic drug flupirtine of the treatment of overactive bladder and associated diseases including urge incontinence, urinary flow problems as a result of prostate hyperplasia and irritable bowl syndrome
NO20070588L (no) Piperidinderivater som NK1-antagonister.
JP2009543825A5 (es)
Plante Hypersomnia in mood disorders: a rapidly changing landscape
JP2006516976A (ja) 機能性腸障害を処置する方法
Buddenkotte et al. Histamine and antihistamines in atopic dermatitis
BRPI0504758A (pt) miméticos de interleucina-8 e métodos para usá-los em prevenção, tratamento, diagnóstico, e melhora dos sintomas de uma doença
Aguilar‐Zafra et al. Pelvic floor dysfunction negatively impacts general functional performance in patients with multiple sclerosis
WO2006006152A3 (en) Treatment of disorders and diseases of the colon
Demir et al. Effect of doxazosin with and without rho-kinase inhibitor on human corpus cavernosum smooth muscle in the presence of bladder outlet obstruction
DOP2003000615A (es) Hidrato estable de un antagonista de receptores muscarinicos
Takeuchi et al. A preliminary examination of the validity and reliability of a new brief rating scale for symptom domains of psychosis: Brief Evaluation of Psychosis Symptom Domains (BE-PSD)
ATE375146T1 (de) Schleimdrogenbasierte lutschtablette gegen entzündliche erkrankungen des mund- und rachenraums
Butris et al. Sleep disruption in older surgical patients and its important implications
Atre et al. Effect of functional strength training versus proprioceptive neuromuscular facilitation on balance and gait in patients with diabetic neuropathy
Meston et al. Sexual Dysfunctions
Thaminy et al. Is chlormethiazole neuroprotective in experimental global cerebral ischemia? A microdialysis and behavioral study
Agrawal et al. Sleep, sleep disorders, and sexual dysfunctions
Elliott Orgasmic and ejaculatory problems in clinical practice
JP7250787B2 (ja) 統合失調症の治療

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150212